Program
zelpultide alfa
Also written as “AT-100” and “Zelpultide alfa”.
Its studies are mostly in Bronchopulmonary Dysplasia · COVID-19, led by Airway Therapeutics.
Furthest: phase 3, since Feb 20, 20253 company-led studies, 1 open or runningNext primary completion: Mar 31, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Airway Therapeutics | 31 open or running | phase 3since Feb 20, 2025 | Dec 4, 2020 | Mar 31, 2028phase 3 · NCT06897839 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 4, 2020First studies: 2 phase 1 studiesFirst studyNCT04662151, NCT04659122
- Feb 20, 2025Phase 3 study in Bronchopulmonary DysplasiaNCT06897839 · 366 planned · Argentina, Belgium, France and more
Ahead
- Mar 31, 2028Primary completion: phase 3 study in Bronchopulmonary DysplasiaNCT06897839
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06897839Bronchopulmonary Dysplasia · Argentina, Belgium, France and more | 3 | Recruiting | Mar 31, 2028 | 366 |
| NCT04662151Bronchopulmonary Dysplasia · United States, Spain | 1 | Completed | Aug 14, 2023 | 37 |
| NCT04659122COVID-19 · United States | 1 | Terminated | Feb 23, 2023 | 5 |
How it is read
Names in the registry
- “AT-100”, 2 entries
- “Zelpultide alfa”, 1 entry
Conditions, from the studies’ own filings
- Bronchopulmonary Dysplasia, 2 studies
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.